News | May 11, 2023
FSD Pharma completes dosing of first cohort in Phase I clinical trial of Lucid-MS
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer
Launches Thalassemia Bal Sewa Yojana portal and releases standard treatment guidelines for sickle cell anemia disease
APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery
Both the companies intend to facilitate faster clinical trial enrollment and provide patients with access to novel medications
The acquisition of ADL BioPharma now makes WACKER owner of the entire plant, with total fermentation capacities of just under 3,000 cubic meters
Biopharma can benefit from the critical enablers of innovation in the private healthcare system in India
Nous-209 has been developed using the Nouscom's viral vector platform
The planned bioprocessing facility would support commercial manufacturing for biotech and pharmaceutical customers across Asia-Pacific.
New agreement applies to the polymers of the Medical Care series portfolio
Subscribe To Our Newsletter & Stay Updated
